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Background: Every year, millions of people are diagnosed with Diabetes mellitus (DM) and the number of new 
and undiagnosed cases continue to rise. Diagnosis of diabetes is usually performed by blood glucose analysis after 
fasting for a certain period. However, this method uses an invasive technique that can cause discomfort and even 
trauma to some patients which could eventually lead to behavioral changes such as avoidance of healthcare and 
laboratory testing. Studies that explore the diagnostic value of salivary glucose are promising due to the non-inva-
siveness of the test procedures and its potential correlation with blood results. 
Material and Methods: The study conducted aimed to determine if salivary glucose can be utilized as an alternative 
to blood glucose in the screening, diagnosis, and monitoring of type 2 diabetes mellitus (T2DM). A total of 75 par-
ticipants were recruited and equally divided into 3 groups (normal fasting glucose, impaired fasting glucose, and 
provisional DM) based on their fasting blood glucose (FBG) level. Blood and unstimulated saliva were collected 
from each participant and were subjected to glucose analysis using the routine glucose oxidase-peroxidase method. 
Results: Using Pearson’s correlation and linear regression, a high degree and significant correlation was observed 
between blood and salivary glucose (r = 0.715, p < 0.001). Further analysis showed that salivary glucose is 88.5% 
sensitive and 61.5% specific with a positive predictive value of 45.8%, and a negative predictive value of 97.1%. 
Conclusions: Salivary glucose is comparable to blood glucose in diagnosing and monitoring T2DM and is conside-
red more advantageous than blood due to its non-invasive nature.




Diabetes remains to be a global health concern with an 
estimated of 422 million people affected worldwide (1). 
In the Philippines, while there are more than 4 million 
Filipino adults reported with the disease, a large unk-
nown number remains undiagnosed. The figure transla-
tes to one in every five Filipinos likely to have diabetes 
or pre-diabetes (2). Early and effective screening of dia-
betes is an important strategy to reduce the incidence of 
the disease and its complications. Blood testing remains 
to be the gold standard in the diagnosis but this can be 
invasive and painful for most patients leading to anxiety, 
risk of infection and the need for skilled phlebotomist 
(3). This painful experience could lead to profound heal-
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th, societal, psychological, and social consequences and 
is highly associated with an avoidance behavior. Fear 
and anxiety to needles may result in non-compliance 
with health care services, such as performance of blood 
tests (4).
Studies that explore the diagnostic value of salivary glu-
cose are promising due to the non-invasiveness of the 
test procedure and its potential correlation with blood re-
sults. The human saliva, an exocrine fluid secretion, has 
high potential for screening health and diseases (5,6). It 
consists of water, electrolytes and variety of proteins like 
enzymes, immunoglobulins, albumin, some polypepti-
des and biomarkers which can be useful for rapid tests 
(5,6). Studies show that proteins present in blood are 
present in saliva as well (5). Therefore, saliva is functio-
nally comparable to blood in reflecting the physiological 
status of the body (7). Because of its potential clinical 
value, there is an increase use of saliva in the diagnosis 
for diseases (6). The collection of saliva is also easier 
and non-invasive compared to collection of blood (5,7).
The study was conducted to determine if salivary gluco-
se can be used as a marker for screening, diagnosing, and 
monitoring type 2 diabetes mellitus (T2DM). Specifica-
lly, it aimed to establish a correlation between variables 
by determining the variation of salivary glucose based 
on changes to the participant’s blood glucose levels. The 
current study was conducted in order to assess the poten-
tial role of saliva as a diagnostic tool by correlating the 
levels of blood and salivary glucose among individuals 
with normal fasting glucose (NFG), impaired fasting 
glucose (IFG), and provisional DM (PDM).  
Material and Methods
-Research Design
A cross-sectional study design was used to compare the 
levels of salivary glucose among individuals with NFG, 
IFG, and PDM. The possible association of salivary glu-
cose with blood glucose was also identified.
-Research Locale
The study was conducted at the Department of Medical 
Technology of Angeles University Foundation. Partici-
pants of the study included 25 males and 50 non-preg-
nant females with ages ranging from 31 to 61 years old 
and are currently residing in Angeles City, Philippines.
-Research Respondents 
A total of 86 participants were initially recruited by the 
researchers and were divided into three groups based 
on their FBG level. However, to equalize the number 
of participants across all the groups, 11 were rando-
mly excluded (n = 75). Post-hoc power analysis using 
G*Power version 3.0.10 was performed and showed that 
based on the number of respondents acquired, the statis-
tical power of the study is 1.00 at two-sided 0.05 level of 
significance with an effect size of 1.00.
Participants included in the study are males and 
non-pregnant females ages 31 years old and above and 
were willing to participate in the study. Subjects exclu-
ded are those with: Type 1 DM, renal disease undergoing 
hemodialysis, diagnosed with endocrine disorders, can-
cer, cardiovascular disease, communicable disease, and 
those undergoing insulin therapy (8,9). All participants 
who passed the inclusion criteria were grouped based on 
their FBG level. FBG-based grouping scheme is based 
on the latest clinical practice guidelines of the American 
Diabetes Association. Respondents with an FBG level 
of <100 mg/dL were classified under Group 1 or those 
with a normal fasting glucose (NFG), those with an FBG 
between 100 to 125 mg/dL were classified under Group 
2 or those with an impaired fasting glucose (IFG), and 
those with an FBG of greater than or equal to 126 mg/dL 
were classified under Group 3 or those who have provi-
sional diabetes mellitus (PDM) (9). 
-Ethical Approval
All procedures performed in this study were in accor-
dance with the ethical standards of the Angeles Univer-
sity Foundation – Center for Research and Development 
Ethics Review Committee (AUF-CRD ERC). Informed 
consent was obtained from all individual participants in-
cluded in the study.
-Patient Preparation and Sample Collection 
Prior to specimen collection, participants were asked to 
fast for a period of 6 to 8 hours. Fasting is essential to 
ensure that all analytes tested are at their basal state. Be-
fore collection of saliva, participants were asked to rinse 
their mouth with distilled water 2 times. Whole saliva 
was collected by passive drooling. Participants were ins-
tructed to spit the pooled saliva in a sterile, disposable 
plastic container over a period of 5 minutes. Samples 
were then stored on ice and was sent to the laboratory 
immediately. Samples were centrifuged at 2000 RPM 
for about 5 minutes. Fasting blood samples were also 
drawn from all participants under aseptic condition and 
both samples were then immediately tested for the level 
of glucose (10-12). 
-Glucose Estimation
The method used for the estimation of glucose in blood 
and saliva were based on the studies of Gupta et al. (13), 
Mascarenhas et al. (14), Soares et al. (15), and Ladgotra 
et al. (11) which utilized routine glucose oxidase-pe-
roxidase end-point method. Concentration of the analyte 
was calculated based on the optical density readings ob-
tained after spectroscopic analysis. 
-Statistical Analysis
SPSS version 20 was used to analyzed the acquired data. 
Pearson’s correlation and linear regression was used 
to determine the relationship of salivary glucose with 
blood glucose. One-way analysis of variance (ANOVA) 
with Scheffe’s Test was used to compare the means of 
both demographic and clinical characteristics across the 
three groups. MedCalc was used to plot for the receiver 
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operating characteristic (ROC) curve. A cut-off point 
with the highest sensitivity, specificity, positive and ne-
gative predictive value in diagnosing T2DM was also 
determined.
Results
Figure 1 summarizes and illustrates the correlational 
analysis using Pearson’s Coefficient between FBG and 
salivary glucose. Correlation coefficient between sali-
vary and blood glucose was computed with significant r 
value of 0.715 (p < 0.001).
Linear regression analysis was also performed and 
showed that salivary glucose (p < 0.001) can signifi-
cantly predict the value of blood glucose. Hence, from 
a given value of salivary glucose, one can compute the 
blood glucose level by using the equation obtained from 
the linear regression analysis. The formula is: [Blood 
Glucose (mg/dL) = 70.086 + (5.860 x Salivary Gluco-
se)].  
Fig. 1: Scatter plot demonstrating the correlation between FBG and salivary glucose.
One-way analysis of variance of age, blood, and salivary 
glucose among the study group was performed (Table 
1). As shown below, there was no significant difference 
for age (p = 0.125) across all three groups. However, 
significant differences were observed with the means of 
both blood (p < 0.001) and salivary glucose (p < 0.001). 
Post-hoc testing was also performed in order to determi-
ne the exact degree of difference among the study group 
(Table 2). The mean salivary and blood glucose levels of 
group 2 (IFG) is significantly lower compared to group 
3 (PDM), but is significantly higher when compared to 
group 1 (NFG) (1 < 2 < 3). This suggests that blood glu-
cose correlates with the levels of glucose in the saliva. 
Cut-off value to diagnose type 2 diabetes mellitus using 
salivary glucose was determined using the ROC curve is 
shown in Figure 2. Among the given cut-off points, the 
optimal value of salivary glucose was >13.22 mg/dL 
which may translate to the idea that patients with salivary 
glucose above this value are most likely to be diabetic. 
PARAMETER GROUP 1 GROUP 2 GROUP 3 p-value
Age 41.1 ± 19.2 48.2 ± 12.1 48.9 ± 12.1 0.125
Blood Glucose (mg/dL) 93.7 ± 6.4 115.8 ± 7.7 189.1 ± 49.6 <0.001*
Salivary Glucose (mg/dL) 5.3 ± 2.5 10.5 ± 4.4 16.3 ± 5.2 <0.001*
Table 1: One-way ANOVA testing of age, blood and salivary glucose among the study group.
*p-value significant at <0.05.
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PARAMETER 1 vs. 2 1 vs. 3 2 vs. 3 Post Hoc
Blood Glucose 0.03* <0.001* <0.001* 1 < 2 < 3
Salivary Glucose <0.001* <0.001* <0.001* 1 < 2 < 3
Table 2: Post-ANOVA testing using Scheffe’s test.
*p-value significant at <0.05.
Fig. 2: ROC curve analysis of salivary glucose.
The ROC curve also yielded a sensitivity of 76.0%, spe-
cificity of 90.0%, positive predictive value of 45.8%, 
and a negative predictive value of 97.1%. These values 
will tell that salivary glucose would correctly identify 
45.8% of the population with high plasma glucose le-
vels. Conversely, the false-negative rate was small re-
lative to the true negative rate, so the probability of an 
individual having a high plasma glucose level with a low 
salivary glucose level is very low, and the negative pre-
dictive value is high (97.1%).
Discussion 
Salivary glucose has been investigated by various stu-
dies as a non-invasive alternative in overcoming the 
problems associated with blood glucose monitoring. But 
because contradicting results are obtained, the idea of 
saliva being an effective replacement for blood gluco-
se is still debatable (16-20). Several studies suggest that 
significant correlation exist between salivary and blood 
glucose and would be helpful in monitoring diabetes. 
Considering that the procedures for glucose monitoring 
today are invasive, saliva can therefore serve as an al-
ternative non-invasive diagnostic fluid to help overco-
me this problem. Saliva testing therefore surpasses all 
of the limitations of venipuncture and provides the ease 
of testing among all age groups (21-23). However, even 
with the existing data regarding the advantage of saliva 
testing and the significant correlation of blood and sali-
vary analytes, the current findings still contradict with 
previous studies. A study conducted by Englander et al. 
(24) expressed their doubt about replacing blood glucose 
with parotid saliva secretion in the diagnosis of diabetes 
mellitus due to its low concentration. Another study con-
ducted by Lopez et al. (25) showed that no significant 
correlation were found between salivary glucose level 
and HbA1c percentage. 
In the study, researchers were able to establish a posi-
tive correlation between FBG and salivary glucose (r 
= 0.715, p < 0.001). Hence, due to the significant po-
sitive correlation seen between salivary glucose and 
FBG, using the equation derived in the linear regression 
analysis, blood glucose can be predicted using a formu-
la with only the salivary glucose levels as the available 
data. The results are similar with previous studies which 
confirms higher levels of salivary glucose in diabetic pa-
tients compared with healthy controls (21-23). Quoting 
the works of several researchers, Abikshyeet et al. (21) 
summarized that there is no single mechanism to explain 
the appearance of glucose in the saliva during periods 
of prolonged hyperglycemia. The small molecular size, 
possible damage in the permeability of basement mem-
brane, changes in the blood vessels, increased leakage 
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from the ductal cells and leakage through the gingival 
crevices may all contribute to the multifactorial cause of 
increased levels of salivary glucose. 
Laboratory analyses using saliva as the specimen sur-
passes all of the limitations of performing venipuncture 
and provides the ease of testing among all age groups 
(14). Tests done on saliva have already made significant 
exposure in the field of diagnostics. Testing of antibo-
dies, unconjugated steroids, hormones and certain drugs 
are some of the adequate evidence that saliva reflects 
blood concentrations of substances accurately. Conside-
ring that blood is the standard for screening, monitoring 
and diagnosing diabetes, saliva, however, transcends se-
veral of its disadvantages and fulfils diagnostic concerns 
as it closely reflects blood levels (26,27).
As noted in the PPV and NPV, saliva can certainly iden-
tify the population whose blood glucose levels are wi-
thin the normal range, thus, sparing them from further 
invasive testing. This strategy will negate the previous 
statements that saliva cannot be effectively used as a 
screening tool for diabetes. Instead, the specimen can be 
used as an initial screening for healthy individuals and 
also a monitoring tool for patients with known hypergly-
cemia. The findings of the study is similar with the con-
clusion made by Hartman et al. (10) that saliva can be 
used as a screening assay for high fasting glucose level. 
However, the presence of co-morbidity, compliance to 
treatment, and the small number of samples may contri-
bute to the possibility of type II statistical error that can-
not be ruled out which calls for a more extensive sample 
to substantiate the usefulness of salivary glucose as a 
biomarker for T2DM. 
Conclusions
Saliva is comparable to blood in terms of screening and 
diagnosing T2DM. Thus, salivary glucose may be used 
as a non-invasive biomarker for screening, diagnosing 
and monitoring T2DM. Since collection of saliva sam-
ples is safe and easy, further studies should be conducted 
to assess the potential of saliva as an alternative diag-
nostic fluid. To the best of our knowledge, there are no 
studies available in peer-reviewed journals regarding sa-
livary glucose and its relation to T2DM conducted in the 
Philippines. Furthermore, the researchers recommend 
further investigations that would fully support the claims 
of this study. A longitudinal large-scale study should be 
conducted due to the limitations of this cross-sectio-
nal study. Other parameters such as glycemic control, 
insulin resistance, and metabolic syndrome are also re-
commended to be included. A more diverse population 
among Filipinos and a homogenous age group are also 
suggested. The researchers also recommend future stu-
dies to elaborate further other salivary analytes that can 
be used for the diagnosis of T2DM as well as other fac-
tors that contribute to their excretion in saliva.
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